Experience with immunomodulatory treatments in Rasmussen’s encephalitis
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
The authors investigated immunomodulatory treatments in 15 patients with Rasmussen encephalitis (RE) (14 with childhood and one with adolescent onset RE). Positive time-limited responses were obtained in 11 patients using variable combinations of corticosteroids, apheresis, and high-dose IV immunoglobulins. Although surgical exclusion of the affected hemisphere is the only treatment that halts disease progression, immunomodulation can be considered when early surgery is not feasible, in late-onset patients with slower disease progression, and in the few cases of bilateral disease.
- Received April 3, 2003.
- Accepted July 31, 2003.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Experience with immunomodulatory treatments in Rasmussen’s encephalitis
- Roy T Daniel, CHUV, Lausanne, Department of Neurosurgery, CHUV, Rue de Bugnon 46, Lausanne 1011, Switzerlandroymercy@hotmail.com
- Jean-Guy Villemure, Chef de service, Department of Neurosurgery, CHUV, Rue de Bugnon 46, Lausanne 1011, Switzerland
Submitted June 19, 2004 - Reply to Daniel
- Tiziana Granata, National Neurological Institute C.Besta, via Celoria 11, 20133 Milano, Italygranata@istituto-besta.it
- Carlo Antozzi
Submitted June 19, 2004
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Case
Refractory status epilepticus secondary to atypical Rasmussen encephalitis successfully managed with aggressive immunotherapySung-Min Cho, Andrew Zeft, Elia Pestana Knight et al.Neurology: Clinical Practice, June 17, 2016 -
Article
Immunomodulation With Azathioprine Therapy in Rasmussen SyndromeA Multimodal EvaluationSerena Pellegrin, Torsten Baldeweg, Suresh Pujar et al.Neurology, October 12, 2020 -
Brief Communications
Long-term selective IgG immunoadsorption improves Rasmussen's encephalitisC. Antozzi, T. Granata, N. Aurisano et al.Neurology, July 01, 1998 -
Brief Communication
Plasmapheresis in Rasmussen's encephalitisP. I. Andrews, M. A. Dichter, S. F. Berkovic et al.Neurology, January 01, 1996